Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > duration

: 6-8 hours

or Hours per application

or ~7-8 hours

Use the filters below to narrow your results.

None (3) · Cephalexin (1) · Ciclopirox (1) · Clindamycin (1) · Clotrimazole (1) · Cyproheptadine (hydrochloride) (1) · Erythromycin (1) · Hydroquinone (1) · Lorazepam (1) · Mupirocin (1) · Nystatin (1) · Penicillin V (phenoxymethylpenicillin) (1) · Phenazopyridine (1) · Torsemide (1)

Ativan (oral, injectable), Loreev XR (1) · Bactroban, Centany (1) · Belsomra (1) · Cleocin (oral, IV); Clindesse, Cleocin (vaginal); Clindets, Cleocin T (topical) (1) · Dayvigo (1) · Demadex, Soaanz (1) · E.E.S., EryPed, Ery-Tab, PCE, Erythrocin (lactobionate IV); topical Erygel, Akne-Mycin; ophthalmic ointment (1) · Keflex, Daxbia, Panixine; mostly prescribed generically (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone) (1) · Mycostatin, Nystop, Nyamyc, Bio-Statin (1) · Pen-V, Veetids (mostly generic) (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1) · Periactin (US brand discontinued; generic widely available) (1) · Pyridium (Rx), Azo Standard, AZO Urinary Pain Relief (OTC) (1) · Quviviq (1)

None (9) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · '"`UNIQ--vote-00000017-QINU`"' Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients'"`UNIQ--ref-00000018-QINU`"'. (1) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) · '"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1) · '"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)

10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) · 100-200 mg PO TID after meals × no more than 2 days when used with concurrent antibiotic (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 250-500 mg PO every 6-8 hours (1) · 250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections (1) · Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID (1) · Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM (1) · Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis (1) · Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days (1) · Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)

0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · 100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · 25 mg, 50 mg tablets (1) · 250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension (1) · 250 mg, 500 mg, 750 mg capsules; 250 mg/5 mL, 125 mg/5 mL suspension; tablets (1) · 250, 500 mg base or stearate tablets; ER tablets; ethyl succinate 200 mg/5 mL suspension; 500 mg, 1 g IV (lactobionate); 2% topical solution/gel; 0.5% ophthalmic ointment (1) · 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1) · 5, 10, 20, 100 mg tablets; 10 mg/mL IV (1) · 75, 150, 300 mg capsules; 75 mg/5 mL solution; 150 mg/mL IV; 1% topical; 2% vaginal cream (1) · 95 mg (OTC), 99.5 mg, 100 mg, 200 mg tablets (1) · Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg (1) · Tablets 4 mg; oral syrup 2 mg/5 mL (1)

10 mg/d (1) · 10 mg/day (anxiety, oral) (1) · 2 g/d typical (1) · 20 mg/d (1) · 200 mg/d typical practical ceiling (1) · 32 mg/day adult; weight-based pediatric ceiling (1) · 4 g/d (1) · 4 g/d (rarely tolerated due to GI effects) (1) · 4% topical; limit duration of use (1) · 4.8 g/d (IV severe infection) (1) · 50 mg/d (1) · BID topical; once daily nail lacquer (1) · Indication-specific (1) · Limit to 48 hours of use to avoid hemolysis and methemoglobinemia (1) · Limit topical to 10-day courses to reduce resistance pressure (1) · Topical: BID; troche: 5×/day (1)

IM (1) · intramuscular (1) · intranasal (1) · intravenous (1) · IV (3) · ophthalmic (1) · Oral (11) · Oral (topical action; minimal systemic absorption) (1) · oral troche (1) · topical (7) · vaginal (3)

30-60 minutes (1) · 30-60 minutes (oral); 5 minutes (IV); 15-30 minutes (IM) (1) · Days (2) · Days for dermatophyte clearance; nail clearance over months (1) · Hours (4) · PO 1 hour; IV 10 minutes (1) · Symptom relief within 30 minutes (1) · Symptom relief within days (1) · Visible lightening at 4-12 weeks (1) · ~30 min (3)

12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)'"`UNIQ--ref-00000023-QINU`"' (1) · 3-4 hours (similar between PO and IV due to high oral bioavailability)'"`UNIQ--ref-00000B46-QINU`"' (1) · 8-16 hours'"`UNIQ--ref-0000001E-QINU`"' (1) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1) · Not meaningfully described — topical local action with minimal systemic absorption'"`UNIQ--ref-00001218-QINU`"' (1) · ~1 hour'"`UNIQ--ref-000004F2-QINU`"' (1) · ~1.5-2 hours'"`UNIQ--ref-00000D3E-QINU`"' (1) · ~12 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~2.5-3 hours'"`UNIQ--ref-00001442-QINU`"' (1) · ~30-60 minutes'"`UNIQ--ref-00000E76-QINU`"' (1) · ~7-10 hours (variable; longer in renal impairment)'"`UNIQ--ref-00000FB4-QINU`"' (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)

90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' (1) · Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) · High (oral)'"`UNIQ--ref-00000FB5-QINU`"' (1) · Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"' (1) · ~44% (1) · ~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"' (1) · ~62% (1) · ~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) · ~82% (1) · ~90% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) · ~90% (oral)'"`UNIQ--ref-00001443-QINU`"' (1) · ~95% (oral)'"`UNIQ--ref-0000001F-QINU`"' (1)

OTC (lower doses) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) · Rx, Schedule IV (US) (3) · [[USLegal:Prescription only|Rx-only]] in US (7) · [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1) · [[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000025-QINU`"' (1)

Showing below up to 16 results in range #1 to #16.

C

L

M

Mupirocin

N

Nystatin

P

S

Suvorexant

T

Torsemide